China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring. 

In this week’s episode of "The Top Line," Fierce Biotech’s Darren Incorvaia chats with Gline about China, artificial intelligence and the exciting year ahead for Roivant’s lead asset brepocitinib. 

To learn more about the topics in this episode: 


After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst 


NIH grant cuts hit women, early-career scientists the hardest: analysis 


Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem' 


Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead 


Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study 

 

China&rsquo;s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.&nbsp;
In this week&rsquo;s episode of "The Top Line," Fierce Biotech&rsquo;s Darren Incorvaia chats with Gline about China, artificial intelligence and the exciting year ahead for Roivant&rsquo;s lead asset brepocitinib.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions">After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/research/nih-grant-cuts-hit-women-early-career-scientists-hardest-analysis-finds">NIH grant cuts hit women, early-career scientists the hardest: analysis</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/roche-pumps-480-million-south-korea-biopharma-industry">Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/lilly-pledges-500m-south-korea-biopharma-industry-following-roches-lead">Lilly pledges $500M to South Korea biopharma industry, following Roche&rsquo;s lead</a>&nbsp;
</li>
</ul>
<ul>
<li>
<a href="https://www.fiercebiotech.com/biotech/pfizer-backed-priovant-scores-again-fast-rising-brepocitinib-mid-stage-study">Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study</a>&nbsp;
</li>
</ul>
&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Roivant’s CEO thinks China is a ‘red herring’

It’s a pivotal year for RNA therapeutics pioneer Ionis Pharmaceuticals. 

After transitioning from a partnering model to a full-ownership strategy following the 2024 approval of Tryngolza, the company is expecting an FDA decision to expand the drug into severe hypertriglyceridemia as its first non-rare-disease indication for a wholly owned product. Meanwhile, potentially game-changing phase 3 readouts are expected from Ionis’ Novartis-partnered lipoprotein(a) candidate and AstraZeneca-partnered ATTR cardiomyopathy program.

In this week’s episode of "The Top Line," Fierce’s Angus Liu interviews Ionis CEO Brett Monia, Ph.D. He discusses the science of antisense oligonucleotides, the significance of the two closely watched upcoming clinical readouts, and what it takes to turn a 30-year-old discovery platform into a full-fledged commercial biotech.

To learn more about the topics in this episode: 
Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion 
'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush 
AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition 
As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra 
Ionis exec shares method to the Madness after 2026 Drug Name Tournament win 
Ionis plots FDA filing after rare neurological disease candidate posts phase 3 win 

It&rsquo;s a pivotal year for RNA therapeutics pioneer Ionis Pharmaceuticals.&nbsp;
After transitioning from a partnering model to a full-ownership strategy following the 2024 approval of Tryngolza, the company is expecting an FDA decision to expand the drug into severe hypertriglyceridemia as its first non-rare-disease indication for a wholly owned product. Meanwhile, potentially game-changing phase 3 readouts are expected from Ionis&rsquo; Novartis-partnered lipoprotein(a) candidate and AstraZeneca-partnered ATTR cardiomyopathy program.
In this week&rsquo;s episode of "The Top Line," Fierce&rsquo;s Angus Liu interviews Ionis CEO Brett Monia, Ph.D. He discusses the science of antisense oligonucleotides, the significance of the two closely watched upcoming clinical readouts, and what it takes to turn a 30-year-old discovery platform into a full-fledged commercial biotech.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/ionis-slashes-tryngolzas-price-tag-down-ahead-anticipated-expansion-wider-shtg-market">Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/biotech/its-going-be-huge-diabolical-molecule-poised-become-biotechs-next-gold-rush">'It&rsquo;s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush</a>&nbsp;</li>
<li><a href="https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition">AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition</a>&nbsp;</li>
<li><a href="https://www.fiercepharma.com/pharma/questions-swirl-around-attr-competition-alnylam-plots-path-market-leadership-amvuttra">As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra</a>&nbsp;</li>
<li><a href="https://www.fiercepharma.com/marketing/ionis-method-madness-its-drug-name-tournament-2026-win">Ionis exec shares method to the Madness after 2026 Drug Name Tournament win</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/biotech/ionis-rare-neurological-disease-candidate-improves-walk-speed-phase-3-win">Ionis plots FDA filing after rare neurological disease candidate posts phase 3 win</a>&nbsp;</li>
</ul>

 A pivotal time for an RNA pioneer 

Theranostics is transforming cancer care, but scaling these treatments requires overcoming operational and workforce challenges. In this episode of The Top Line, Curium’s Mike Patterson discusses how access, safety and trust are shaping the next phase of growth for targeted radiopharmaceutical therapies.

 

Patterson explains why strong coordination across ordering, manufacturing and distribution is essential to delivering therapies on time. He also explores how building trust with physicians, care teams and patients requires education, consistent communication and reliable support at every stage of the treatment process.

 

As theranostics expands into community settings, new challenges are emerging. Workforce shortages, training needs and the importance of standardized practices are key considerations for scaling safely. Patterson shares how industry collaboration can help address these gaps while maintaining high standards of care.

 

He also outlines a future defined by greater access, reduced travel burdens and a more seamless patient experience. Listen to the full episode to learn how Curium is working to make theranostics more accessible across the United States.

Theranostics is transforming cancer care, but scaling these treatments requires overcoming operational and workforce challenges. In this episode of The Top Line, Curium&rsquo;s Mike Patterson discusses how access, safety and trust are shaping the next phase of growth for targeted radiopharmaceutical therapies.
&nbsp;
Patterson explains why strong coordination across ordering, manufacturing and distribution is essential to delivering therapies on time. He also explores how building trust with physicians, care teams and patients requires education, consistent communication and reliable support at every stage of the treatment process.
&nbsp;
As theranostics expands into community settings, new challenges are emerging. Workforce shortages, training needs and the importance of standardized practices are key considerations for scaling safely. Patterson shares how industry collaboration can help address these gaps while maintaining high standards of care.
&nbsp;
He also outlines a future defined by greater access, reduced travel burdens and a more seamless patient experience. Listen to the full episode to learn how Curium is working to make theranostics more accessible across the United States.

Scaling theranostics through access, safety and trust (Sponsored)

Speed, precision, and visibility are critical to clinical trial success, and logistics plays a central role in delivering all three. In this interview, Manishaa O’Brien, director of commercial operations at Marken UPS Healthcare Precision Logistics, shares how the Laboratory Advantage service line is helping central labs and sponsors accelerate timelines while maintaining sample integrity and compliance.

O’Brien discusses how Marken’s global network, combined with its air and ground fleet, connects clinical sites worldwide and expands access to diverse patient populations. She explains how enhanced tracking, integrated data systems and a 99.5% on-time performance rate support reliable, end-to-end visibility for lab partners. Dedicated account management and tailored logistics solutions further strengthen collaboration and help ensure regulatory requirements are met.

The conversation also explores key trends shaping the future of clinical trial logistics, including increasing complexity, the rise of AI-driven routing and the growing importance of sustainability. From automation to eco-friendly packaging innovations, Marken is building a more efficient and resilient supply chain. Watch the full interview to learn how these advancements are helping clinical trials move faster and smarter.

Speed, precision, and visibility are critical to clinical trial success, and logistics plays a central role in delivering all three. In this interview, Manishaa O&rsquo;Brien, director of commercial operations at Marken UPS Healthcare Precision Logistics, shares how the Laboratory Advantage service line is helping central labs and sponsors accelerate timelines while maintaining sample integrity and compliance. O&rsquo;Brien discusses how Marken&rsquo;s global network, combined with its air and ground fleet, connects clinical sites worldwide and expands access to diverse patient populations. She explains how enhanced tracking, integrated data systems and a 99.5% on-time performance rate support reliable, end-to-end visibility for lab partners. Dedicated account management and tailored logistics solutions further strengthen collaboration and help ensure regulatory requirements are met. The conversation also explores key trends shaping the future of clinical trial logistics, including increasing complexity, the rise of AI-driven routing and the growing importance of sustainability. From automation to eco-friendly packaging innovations, Marken is building a more efficient and resilient supply chain. Watch the full interview to learn how these advancements are helping clinical trials move faster and smarter.

Roivant’s CEO thinks China is a ‘red herring’

The Top Line

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips